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Abstract
In clinical trials, the response of a given subject often depends on the selected treat-
ment as well as on some covariates. We study optimal approximate designs of experiments
in the models with treatment and covariate effects. We allow for the variances of the re-
sponses to depend on the chosen treatments, which introduces heteroscedasticity into the
models. For estimating systems of treatment contrasts and linear functions of the covari-
ates, we extend known results on D-optimality of product designs by providing product
designs that are optimal with respect to general eigenvalue-based criteria. In particular,
A- and E-optimal product designs are obtained. We then formulate a method based
on linear programming for constructing optimal designs with smaller supports from the
optimal product designs. The sparser designs can be more easily converted to practically
applicable exact designs. The provided results and the proposed sparsification method
are demonstrated on some examples.
1 Introduction
In the experiments performed to estimate the effects of a selected set of treatments, it is com-
mon that the responses are also affected by some other experimental conditions (the covariates
– e.g., time trend, block effects, the ages or the gender of the subjects in a clinical trial). The
effects of the covariates are traditionally considered to be nuisance effects in the experimental
design literature (e.g., Cox [1951], Majumdar and Notz [1983], Atkinson and Donev [1996],
Jacroux et al. [1997], Rosa and Harman [2016]). Recently, Atkinson [2015] suggested that
particularly with the growing importance of personalized medicine, the covariate effects may
also be of prominent interest.
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Moreover, the interest often lies in some functions of the model parameters rather than
in the parameters themselves. The comparisons of test treatments with a control or with
the placebo is a common example, especially in clinical trials. The design and analysis are
sometimes further complicated by the presence of heteroscedasticity – the responses under
different treatments may have different variances. In the present paper, we study optimal
approximate designs in heteroscedastic models with treatment effects and covariate effects
where there is interest in a set of treatment contrasts and in a set of linear combinations of
the covariate effects.
For the abovementioned settings, Atkinson [2015] studied D-optimality in a model with
only two treatments. Wang and Ai [2016] extended his results by providingD-optimal product
designs for arbitrary numbers of treatments. The D-optimality is the most popular criterion
in optimal design literature and is particularly nice to work with analytically. However, if the
interest lies in a set of treatment contrasts (e.g., in the test treatment-control comparisons,
which are a natural choice when placebo is included in the clinical trial), D-optimality tends
to ignore the special interest in the chosen contrasts; i.e., this criterion tends to select designs
that do not provide more information on the contrasts of interest compared to other treatment
contrasts. As such, D-optimality is generally not recommended for such experimental interests
(cf. Hedayat et al. [1988], Morgan and Wang [2010]). This also corresponds to the observation
by Wang and Ai [2016] that if the experimental objective is to estimate the test treatment-
control comparisons and all covariate effects, then the D-optimal designs are the same as if
there was interest in all covariate effects and a uniform interest in all the treatments. That is,
in such a case, the D-optimality does not place any special emphasis on the test treatment-
control comparisons.
In contrast, the A-optimality criterion possesses a natural statistical interpretation for the
considered settings – it minimizes the average variance for the linear functions of interest.
Hence, A-optimality is very popular for the comparisons with the control (e.g., see Hedayat
et al. [1988]). Recently, E-optimality was also argued to be meaningful for estimating treat-
ment contrasts (e.g., Morgan and Wang [2011], Rosa [2018]). In this paper, we therefore
extend the results by Wang and Ai [2016] to other eigenvalue-based optimality criteria (see
Section 2). In particular, we obtain Φp-optimal product designs for the other Kiefer’s Φp-
optimality criteria besides D-optimality, including A- and E-optimality.
The observation that the product designs are generally optimal for multi-factor models
(like the treatment-covariate one) is extensively used in the literature; e.g., see Schwabe and
Wierich [1995], Schwabe [1996], Rodriguez and Ortiz [2005], Graßhoff et al. [2007]. One
drawback of the optimal product designs is that they have large supports, and therefore it is
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sometimes difficult to construct designs for the actual experiments from the product designs
by rounding procedures1 (e.g., the well-known efficient rounding procedure by Pukelsheim
and Rieder [1992]). However, in Section 3, we provide an entire class of Φ-optimal designs
characterized by linear constraints. This allows us to formulate a linear programming method
for constructing optimal designs with smaller supports from the optimal product designs.
Similar approach was employed by Rosa and Harman [2016] in a homoscedastic model, where
the covariate effects were considered to be nuisance parameters.
The application of the theoretical results, and in particular the construction of the opti-
mal designs with sparser supports and their usefulness in obtaining efficient exact designs of
experiments is demonstrated on some examples in Section 4.
1.1 Notation
By 1n and 0n, we denote the vector of ones and the vector of zeros in Rn, respectively. The
vector ei has 1 on the ith position and zeros elsewhere. The identity matrix is denoted by
In and the m × n matrix of zeros is denoted by 0m×n. For brevity, we sometimes omit the
subscripts expressing the dimensions. The expression diag(a1, . . . , an), where ai ∈ R, denotes
the diagonal matrix with a1, . . . , an on diagonal. If A and B are matrices, diag(A,B) denotes
the corresponding block diagonal matrix. The smallest eigenvalue of a nonnegative definite
matrix A is denoted by γmin(A). Given a matrix A, the symbol A− denotes a generalized
inverse of A, and A+ is the Moore-Penrose pseudoinverse of A.
1.2 The model
Consider the model
y(i, k) = τi + µ+ g
T (k)β + ε(i, k), (1)
where i ∈ {1, . . . , v1} is the chosen treatment and k ∈ T, |T| = d, represents the chosen
covariates. The vector τ = (τ1, . . . , τv1) represents the treatment effects, µ is the constant
term, β = (β1, . . . , βv2)T are the covariate effects, and g(k) ∈ Rv2 is the regression function for
the covariates k. The errors ε are uncorrelated with zero mean, and their variance depends
on the treatment chosen for the ith trial: Var(ε(i, k)) = σ2/λi. The positive function λ :
{1, . . . , v1} → R++ is called the efficiency function and is assumed to be known.
1The product designs, like other approximate designs, specify only proportions of trials to be performed
for the particular experimental conditions, as will be formalized later. To obtain actual integer numbers of
trials, some rounding is generally performed.
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We assume that the set T of all potential covariates is finite, which is often the case in
practice: the covariates are either naturally discrete (e.g., blocks) or the continuous covariates
are discretized. For ease of notation, we number the covariates: T = {1, . . . , d}. Model (1)
can be expressed in a compact form as y(i, k) = fT (i, k)θ + ε(i, k), where θ = (τT , µ, βT )T ,
and f(i, k) = (eTi , 1,gT (k))T is the regression function for the given i and k.
The approximate design ξ (or the design ξ, in short) is a probability measure on the
design space X = {1, . . . , v1} ⊗ {1, . . . , d}; i.e., ξ is a nonnegative function from X to R that
satisfies
∑
i,k ξ(i, k) = 1. The value ξ(i, k) represents the proportion of all trials that are
performed with treatment i and covariates k. The exact design ξe, which describes an actual
experiment consisting of n trials, specifies the number of trials ξe(i, k) that are performed with
treatment i and covariates k for each i and k. The limit on the number of trials means that∑
i,k ξe(i, k) = n. In this paper, we consider approximate designs, unless specified otherwise.
The moment matrix of a design ξ is M(ξ) =
∑
i,k ξ(i, k)λif(i, k)f
T (i, k). Let h(k) :=
(1,gT (k))T ; then, M(ξ) can be expressed in the block form
M(ξ) =
[
M11(ξ) M12(ξ)
MT12(ξ) M22(ξ)
]
,
whereM11(ξ) = diag(λ1w1, . . . , λv1wv1),M12(ξ) =
(∑
k λ1ξ(1, k)h(k), . . . ,
∑
k λv1ξ(v1, k)h(k)
)T
and M22(ξ) =
∑
i,k λiξ(i, k)h(k)h
T (k).
The experimental interest in a set of s1 treatment contrasts QT1 τ and in a set of s2 linear
functions of the covariate effects KTβ, where Q1 ∈ Rv1×s1 and K ∈ Rv2×s2 , can be expressed
as AT θ, where
A =
[
Q1 0v1×s2
0(v2+1)×s1 Q2
]
= diag(Q1,Q2)
and QT2 = (0s2 ,KT ). Because QT1 τ is a system of contrasts, the matrix Q1 satisfies QT1v1 =
0s1 . The subsystem AT θ is estimable under ξ if C(A) ⊆ C(M(ξ)). In such a case, we say
that ξ is feasible for AT θ. The constant term µ is not estimable because of the presence of
the treatment effects; therefore, the first row of matrix Q2 is a row of zeros, as formulated
above. Let both Q1 and K be of full column rank. We also suppose that there is interest
in all treatments; i.e., no row of Q1 is a row of zeros. The information matrix for AT θ of a
feasible ξ is NA(ξ) = (ATM−(ξ)A)−1.
A design ξ∗ is Φ-optimal if it maximizes Φ(NA(ξ)) for a given functional Φ of the in-
formation matrix. For example, ξ∗ is D-optimal if it maximizes det(NA(ξ)), A-optimal if
it maximizes 1/tr(N−1A (ξ)) and E-optimal if it maximizes γmin(NA(ξ)). The mentioned op-
timality criteria can be extended to an entire class of the so-called Kiefer’s Φp-optimality
4
criteria, p ∈ [−∞, 0] (see Pukelsheim [1993], Chapter 6):
Φp(N) =

(det(N))1/s, p = 0;
( 1s tr(N
p))1/p, p ∈ (−∞, 0);
γmin(N), p = −∞,
where N is an s × s positive definite matrix. The criteria of D-, A- and E-optimality are
obtained by setting p = 0, −1 and −∞, respectively.
We require that the optimality criteria possess some basic properties so that they correctly
measure the amount of the obtained information. In particular, the criteria must be positively
homogeneous, concave, nonnegative, nonconstant and upper semicontinuous; such criteria are
called information functions (Pukelsheim [1993], Chapter 5). The optimality criteria are
usually eigenvalue based, i.e., they depend only on the eigenvalues of the information matrix.
In the present paper, we restrict ourselves to eigenvalue-based information functions. One
common class of such functions is the class of the Φp-criteria.
If the system of interest is rank deficient (i.e., if A is not of full column rank), then
ATM−(ξ)A is never non-singular, and therefore (ATM−(ξ)A)−1 does not exist. In such
cases, especially for eigenvalue-based optimality criteria, the information matrix for AT θ is
set to be NA(ξ) = (ATM−(ξ)A)+; see Section 8.18 by Pukelsheim [1993]. The Φp-optimality
criteria are then defined on the positive eigenvalues ofNA(ξ). The system τi−τ¯ (i = 1, . . . , v1)
for estimating centered treatment effects, represented by Q1 = Iv1 − 1v11Tv1/v1, is a simple
example of a rank-deficient system of treatment contrasts.
1.3 Marginal models
For the first marginal model of (1), we consider the heteroscedastic model for treatment effects
y(i) = τi + ε(i), (2)
where Var(ε(i)) = σ2/λi. We denote the marginal treatment design w as the approximate
design in (2). That is, w specifies v1 nonnegative treatment weights that sum to one; we denote
these weights as w1, . . . , wv1 . The moment matrix of w is M1(w) = diag(λ1w1, . . . , λv1wv1),
and w is feasible for QT1 τ if wi > 0 for all i = 1, . . . , v1, denoted as w > 0. The information
matrix for QT1 τ of w > 0 is NQ1(w) = (QT1M
−1
1 (w)Q1)
−1.
For the second marginal model, we consider the homoscedastic model for covariates with
constant term:
y(k) = µ+ gT (k)β + εk. (3)
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Then, themarginal covariate design α is an approximate design in (3). The marginal covariate
design is analogously characterized by the d covariate weights α1, . . . , αd, and its moment
matrix is
M2(α) =
d∑
k=1
αkh(k)h
T (k) =
[
1
∑
k αkg
T (k)∑
k αkg(k)
∑
k αkg(k)g
T (k)
]
.
The subsystem KTβ is estimable if C(Q2) ⊆ C(M2(α)), which is equivalent to C(K) ⊆ S(α),
where S(α) =
∑
k αkg(k)g
T (k) − (∑k αkg(k))(∑k αkgT (k)) is the Schur complement of
M2(α). The Schur complement of a nonnegative definite matrix in the block form
B =
[
B11 B12
BT12 B22
]
(4)
is BS = B22 −BT12B−111 B12. More precisely, BS is the Schur complement of B11 in B.
The information matrix for KTβ of a feasible α is NK(α) = (QT2M
−
2 (α)Q2)
−1. The
information matrix can be expressed using the Schur complement, because the matrix
G =
[
B−111 +B
−1
11 B12B
−
SB
T
12B
−1
11 −B−111 B12B−S
−B−SBT12B−111 B−S
]
, (5)
is a generalized matrix of an arbitrary nonnegative definite matrixB given by (4); see Theorem
9.6.1 by Harville [1997]. Formula (5) implies for M2(α) that NK(α) = (KTS−(α)K)−1.
For a design ξ in model (1), the marginal treatment design w of ξ is given by wi =∑
k ξ(i, k) (i = 1, . . . , v1) and the marginal covariate design α of ξ is given by αk =
∑
i ξ(i, k)
(k = 1, . . . , d).
2 Optimal product designs
The product design ξ = w ⊗ α of the marginal designs w and α satisfies ξ(i, k) = wiαk
(i = 1, . . . , v1, k = 1, . . . , d).
Proposition 1. If w > 0 and if α is feasible for KTβ, then ξ = w ⊗ α is feasible for AT θ
and its information matrix is
NA(w ⊗ α) =
[
NQ1(w) 0
0 (
∑
i λiwi)NK(α)
]
. (6)
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Proof. For ξ = w⊗α, a generalized inverse ofM(ξ) can be expressed as in (5) using the Schur
complement
S1(ξ) = M22(ξ)−MT12(ξ)M−111 (ξ)M12(ξ)
=
( v1∑
i=1
λiwi
)( d∑
k=1
αkh(k)h
T (k)− (
d∑
k=1
αkh(k))(
d∑
k=1
αkh
T (k))
)
=
( v1∑
i=1
λiwi
)[0 0T
0 S(α)
]
.
Observe that M11(ξ) = M1(w) and that
M−111 (ξ)M12(ξ) = diag((λ1w1)
−1, . . . , (λv1wv1)
−1)

λ1w1
...
λv1wv1
 d∑
k=1
αkh
T (k)
= 1v1
d∑
k=1
αkh
T (k).
Because QT1 1 = 0, we obtain QT1M
−1
11 (ξ)M12(ξ) = 0. Let us calculate M(ξ)M
−(ξ)A, where
M−(ξ) is given by (5). By employing the abovementioned observations, it is straightforward
to show that M(ξ)M−(ξ)A = diag(Q1,S1(ξ)S−1 (ξ)Q2). Because α is feasible for K
Tβ, we
have C(K) ⊆ C(S(α)), which implies C(Q2) ⊆ C(S1(ξ)). Then, S1(ξ)S−1 (ξ)Q2 = Q2, which
yields M(ξ)M−(ξ)A = A; i.e., ξ is feasible for AT θ.
The information matrix of ξ can be expressed using the same generalized inverse M−(ξ)
and the fact that M−111 (ξ)M12(ξ)Q1 = 0:
N−1A (ξ) =
[
QT1M
−1
1 (w)Q1 0
0 QT2 S
−
1 (ξ)Q2
]
,
which is equivalent to (6).
The following preliminary lemma shows that no design is better with respect to any
eigenvalue-based criterion than the product of its marginals.
Lemma 1. Let Φ be an eigenvalue-based information function, let ξ be a design in model (1)
and let w and α be its marginal designs. Then, Φ(NA(ξ)) ≤ Φ(NA(w ⊗ α)).
Proof. Similarly to the proof of Lemma 3.1 by Schwabe [1996], let us consider the modification
of model (1), where τi is changed to −τi. This corresponds to the change in regressors from
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f(i, k) = (eTi , 1,g
T (k)) to f˜(i, k) = (−eTi , 1,gT (k)). The moment matrix M˜(ξ) in the modified
model is
M˜(ξ) =
[
M11(ξ) −M12(ξ)
−MT12(ξ) M22(ξ)
]
.
Then, the information matrix changes from NA(ξ) to
N˜A(ξ) =
[
−I 0
0 I
]
NA(ξ)
[
−I 0
0 I
]
.
Because the matrix diag(−I, I) is orthogonal, the information matrices NA(ξ) and N˜A(ξ)
have the same eigenvalues; hence Φ(NA(ξ)) = Φ(N˜A(ξ)). From concavity of Φ it follows that
Φ(
1
2
(NA(ξ) + N˜A(ξ))) ≥ 1
2
Φ(NA(ξ)) +
1
2
Φ(N˜A(ξ)) = Φ(NA(ξ)).
Moreover, (NA(ξ) + N˜A(ξ))/2 = diag(N11(ξ),N22(ξ)) =: N∗(ξ). By expressing the general-
ized inverse M−(ξ) through the Schur complement S1(ξ) (see (5)), we obtain that N∗(ξ) =
(ATdiag(M−111 +M
−1
11 M12S
−
1 M
T
12M
−1
11 ,S
−
1 )A)
−1. Moreover, diag(M−111 +M
−1
11 M12S
−
1 M
T
12M
−1
11 ,S
−
1 ) 
diag(M−111 ,S
−
1 ), which implies that N∗(ξ)  (ATdiag(M−111 ,S−1 )A)−1 = NA(w ⊗ α). Hence,
Φ(NA(w ⊗ α)) ≥ Φ(N∗(ξ)) ≥ Φ(NA(ξ)).
For any eigenvalue-based Φ, Lemma 1 implies that if there exists a Φ-optimal design, then
there exists a product design that is Φ-optimal among all designs. In particular, if ξ∗ is Φ-
optimal with marginal treatment design w∗ and marginal covariate design α∗, then w∗ ⊗ α∗
is Φ-optimal.
Theorem 1. Let Φ be an eigenvalue-based information function. Then, if there exists a Φ-
optimal design for AT θ in (1), then there exists a product design in (1) that is Φ-optimal for
AT θ.
Theorem 1 shows that to obtain a Φ-optimal design it suffices to find a Φ-optimal product
design. ForD-optimality, the problem of finding a Φ-optimal product design simplifies because
of its multiplicative form:
det(NA(w ⊗ α)) = (
v1∑
i=1
λiwi)
s2 det(NQ1(w)) det(NK(α)).
This means that the optimal w and α can be computed separately, which was extensively
used by Wang and Ai [2016].
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For the other Φp-optimality criteria, we reduce the complexity of the problem as follows:
For p ∈ (−∞, 0), we have
Φp(NA(w ⊗ α)) =
(
s−1
(
tr(NpQ1(w)) + (
∑
i
λiwi)
ptr(NpK(α))
))1/p
. (7)
The additive form allows one to first calculate the covariate design α∗, which is Φp-optimal
in the marginal model (3), by maximizing Φp(NK(α)) and then calculate the corresponding
optimal w∗ by maximizing Φp(NA(w ⊗ α∗)) over all w. Then, from (7) it follows that the
product design w∗ ⊗ α∗ is Φp-optimal. Analogously, to calculate the E-optimal (p = −∞)
product design, one can first find the E-optimal α∗ in (3), which maximizes γmin(NK(α)),
and then the optimal w∗ that maximizes γmin(NA(w⊗α∗)). Therefore, for any Φp-optimality
criterion, the optimization problem of size v1 · d can be split into two maximization problems
of sizes d and v1, respectively, even for p other than 0.
Theorem 2. (i) Let p ∈ (−∞, 0), let α∗ be Φp-optimal for KTβ in (3) and denote ϕ∗ =
tr(NpK(α
∗)). Let w∗ maximize Φp(NA(w ⊗ α∗)) = (s−1(tr(NpQ1(w)) + (
∑
i λiwi)
pϕ∗))1/p.
Then, ξ∗ = w∗ ⊗ α∗ is Φ-optimal for AT θ in (1).
(ii) Let α∗ be E-optimal for KTβ in (3) and let w∗ maximize γmin(NA(w ⊗ α∗)). Then,
ξ∗ = w∗ ⊗ α∗ is E-optimal for AT θ in (1).
Theorem 2 shows that α∗ in the Φp-optimal product design w∗ ⊗ α∗ is the Φp-optimal
marginal covariate design, but w∗ is generally not Φp-optimal in (2). Due to heteroscedasticity,
a slight correction (represented by ϕ∗) needs to be present to calculate the “optimal” marginal
treatment design w∗.
3 Optimal non-product designs
In the previous section, we showed that to calculate an optimal design, it suffices to restrict
oneself to the product designs. However, in model (1), besides an optimal product design,
there usually exists a rich class of optimal designs that are not of the product form. Fortu-
nately, once a Φ-optimal product design ξ∗ is found, other Φ-optimal designs can generally
be constructed from ξ∗. The following theorem provides such a construction.
Theorem 3. Let Φ be an eigenvalue-based information function and let ξ∗ = w∗ ⊗ α∗ be the
Φ-optimal product design for AT θ. Let ξ satisfy M(ξ)GA = A, where
G = diag(M−11 (w
∗), (
∑
i
λiw
∗
i )
−1M−2 (α
∗))
9
and where M−2 (α
∗) is any generalized inverse of M2(α∗). Then, ξ is Φ-optimal for AT θ.
In particular, let ξ satisfy
wi = w
∗
i , i = 1, . . . , v1 (8)[
1
w∗1
d∑
k=1
ξ(1, k)g(k), . . . ,
1
w∗v
d∑
k=1
ξ(v1, k)g(k)
]
Q1 = 0v2×s1 , (9)

∑
k(ξ(1, k)− w∗1α∗k)gT (k)
...∑
k(ξ(v1, k)− w∗v1α∗k)gT (k)
S−(α∗)K = 0v1×s2 , (10)
( v1∑
i=1
λiw
∗
i
)−1(
(
∑
i,k
λiξ(i, k)g(k)g
T (k))− (
∑
i,k
λiξ(i, k)g(k))
v2∑
k=1
α∗kg
T (k)
)
S−(α∗)K = K,
(11)
where w is the marginal treatment design of ξ. Then, ξ is Φ-optimal for AT θ.
Proof. Lemma 1 by Rosa and Harman [2016] shows that if M˜ is a non-negative definite matrix
and if a design ξ satisfies M(ξ)M˜−A = A, then ξ is feasible for AT θ and ATM−(ξ)A =
ATM˜−A. We choose M˜ = diag(M1(w∗), (
∑
i λiw
∗
i )M2(α
∗)) and
G = diag(M−11 (w
∗), (
∑
i
λiw
∗
i )
−1M−2 (α
∗)).
ThenG is a generalized inverse of M˜, and any ξ satisfyingM(ξ)GA = A satisfiesATM−(ξ)A =
ATGA = N−1A (ξ
∗); i.e., such ξ is Φ-optimal.
For the second part, for the generalized inverse of M2(α∗) we choose
M−2 (α
∗) =
[
1 + (
∑
k α
∗
kg
T (k))S−(α∗)(
∑
k α
∗
kg
T (k)) −∑k α∗kgT (k)S−(α∗)
−S−(α∗)∑k α∗kg(k) S−(α∗)
]
. (12)
The condition M(ξ)GA = A consists of the following equalities:
M11(ξ)M
−1
1 (w
∗)Q1 = Q1 (13)
M12(ξ)M
−
2 (α
∗)Q2 = 0 (14)
MT12(ξ)M
−1
1 (w
∗)Q1 = 0 (15)
(
v1∑
i=1
λiw
∗
i )
−1M22(ξ)M−2 (α
∗)Q2 = Q2 (16)
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Because no row of Q1 is a row of zeros, condition (13) implies that wi = w∗i . Equality (14)
can be expressed as
(
∑
k λ1ξ(1, k)g
T (k)
...∑
k λvξ(v, k)g
T (k)
−

λ1w
∗
1
...
λvw
∗
v
 d∑
k=1
α∗kg
T (k)
)
S−(α∗)K = 0,
which can be simplified to (10). Equality (15) can be simplified to[
1
w∗1
v2∑
k=1
ξ(1, k)g(k), . . . ,
1
w∗v
v2∑
k=1
ξ(v, k)g(k)
]
Q1 = 0.
Finally, condition (16) can be expressed by the following equalities:
(
(
∑
i,k
λiξ(i, k)g
T (k))− (
v∑
i=1
λiw
∗
i )
v2∑
k=1
α∗kg
T (k)
)
S−(α∗)K = 0T , (17)
( v1∑
i=1
λiw
∗
i
)−1(
(
∑
i,k
λiξ(i, k)g(k)g
T (k))− (
∑
i,k
λiξ(i, k)g(k))
v2∑
k=1
α∗kg
T (k)
)
S−(α∗)K = K.
However, (17) can be simplified to
( v1∑
i=1
λi
v2∑
k=1
(ξ(i, k)− w∗i α∗k)gT (k)
)
S−(α∗)K = 0T ,
which follows from (10).
Because the conditions in Theorem 3 are linear, optimal designs satisfying these conditions
can be calculated via linear programming (LP) once w∗ and α∗ are computed:
min{cTx | x ∈ Rv1d,Cx = b,x ≥ 0}, (18)
where x represents the v1d design values, Cx = b consists of the conditions given by Theorem
3 and of the design constraint
∑
j xj = 1. The vector c can be chosen arbitrarily, as the
objective is to find any x ≥ 0 that satisfies Cx = b.
The possibility of employing linear programming has two crucial advantages. The more
obvious one is that it is relatively simple to solve the LP problems, and most mathematical
software packages (e.g., MATLAB and R) contain reliable and fast LP solvers. The other
advantage is that the vertices of the set of the feasible solutions of (18) have high numbers of
zeroes among all feasible solutions; for technical details, see, e.g., Theorem 2.4 by Bertsimas
and Tsitsiklis [1997]. In fact, any vertex solution of (18) is guaranteed to have at least
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v1d−r zeros, where r = rank(C). This is beneficial, because such designs with small supports
can then be obtained by solving the LP problem via the simplex method, as this method
provides vertex solutions. Note that the MATLAB implementation of the interior point
method also seems to provide vertex solutions. Theorem 3 therefore allows us to formulate a
linear programming “sparsification” method of the product designs based on solving (18). In
Section 4, we demonstrate the applicability of this method.
Remarks
• For simpler settings (e.g., in the homoscedastic case or if the interest lies in QT1 τ only),
the obtained results simplify correspondingly. For instance, if the interest lies only in
a set of treatment contrasts (i.e., A = (QT1 ,0)T ), then the product design w∗ ⊗ α
is Φ-optimal for any marginal covariate design α, where w∗ is a Φ-optimal marginal
treatment design for QT1 τ . Moreover, for such AT θ, any design ξ that satisfies (9)
and whose marginal treatment design is w∗ is Φ-optimal. The designs satisfying (9)
were denoted as resistant to nuisance effects in a slightly different context by Rosa and
Harman [2016]. In the present settings, designs satisfying (8) and (9) may be called
covariate resistant: if the interest lies only in QT1 τ , then no relevant information is lost
under such designs due to the presence of covariates.
• In the case of a rank-deficient system, both the results of Section 2 and of Section 3
hold, as the proofs in Section 2 can be easily adapted to NA(ξ) = (ATM−(ξ)A)+ and
Theorem 3 ensures that ATM−(ξ)A = ATM˜−A, which also implies the equality of the
rank-deficient information matrices.
• If a Φ-optimal design ξ∗ is known, other Φ-optimal designs can trivially be found by
solving the linear equality
∑
i,k ξ(i, k)f(i, k)f
T (i, k) = M(ξ∗) that guarantees that the
design ξ has the same moment matrix as ξ∗. The conditions in Theorem 3 are more
general, as it can be shown that any design satisfying M(ξ) = M(ξ∗) also satisfies
M(ξ)GA = A withG given by Theorem 3. Conditions (8)-(9) can generally be satisfied
also by designs ξ that do not have the same moment matrix as ξ∗; only the information
matrices of ξ and ξ∗ are guaranteed to coincide.
4 Examples
Example 1. Consider a model with effects of v2 continuous covariates
y(i, z) = τi + µ+ z
Tβ + ε,
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i\k 1 2 3 4 5 6 7 8
1 0.0295 0.0295 0.0295 0.0295 0.0295 0.0295 0.0295 0.0295
2 0.0477 0.0477 0.0477 0.0477 0.0477 0.0477 0.0477 0.0477
3 0.0477 0.0477 0.0477 0.0477 0.0477 0.0477 0.0477 0.0477
Table 1: Optimal product design for Example 1. The indices k = 1, . . . , 8 denote the active
covariate values z = (−1,−1,−1)T , (−1,−1, 1)T , . . . , (1, 1, 1)T arranged in the lexicographical
order; the treatments are denoted by i = 1, 2, 3.
i\k 1 2 3 4 5 6 7 8
1 0.0378 0 0.0212 0.0591 0.0212 0.0591 0.0378 0
2 0 0.1909 0 0 0 0 0.1909 0
3 0.1909 0 0 0 0 0 0 0.1909
Table 2: Optimal non-product design for Example 1; the notation is the same as in Table 1.
where z ∈ [−1, 1]v2 , as in Example 2 by Wang and Ai [2016]. By a discretization of the
continuous covariates, say zi ∈ {±j/10 | j = 0, . . . , 10}, the model becomes a special case
of (1). Suppose that we wish to obtain A-optimal designs for estimating the comparisons
with the control τi − τ1, i = 2, . . . , v1 and all the covariate effects; i.e., Q = (−1v1−1, Iv1−1)T
and K = Iv2 . Then, the marginal covariate design α∗ that is uniform on {−1, 1}v2 is A-
optimal for KTβ. The corresponding information matrix is NK(α∗) = Iv2 , and hence ϕ∗ =
tr(I−1v2 ) = v2. Then, the optimal marginal treatment design w
∗ can be obtained by minimizing
tr(QTM−11 (w)Q) + v2(
∑
i λiwi)
−1.
Let v1 = v2 = 3 and let λ1 = 9, λ2 = λ3 = 1; i.e., the observations under the control
treatment have smaller variances. Then, the vector of the optimal treatment weights given
by w∗ is (0.236, 0.382, 0.382)T , and hence the product design ξ∗ = w∗ ⊗ α∗ (see Table 1) is
A-optimal for AT θ. As observed in Theorem 2, the optimal treatment design w∗ depends on
ϕ∗, which is equal to the number of covariates v2 in the current example. Figure 1 depicts
the dependence of w∗1 on v2 for the abovementioned settings.
An A-optimal design, say ξ∗s , that is supported on a smaller number of design points was
computed by solving the linear program (18). Although ξ∗s was allowed to attain non-zero
values even outside of the support of ξ∗, it turns out that the support of ξ∗s is a subset of
the support of ξ∗. Therefore, ξ∗s can also be expressed by considering only z ∈ {−1, 1}3, see
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i\k 1 2 3 4 5 6 7 8
1 2 0 1 3 1 3 2 0
2 0 9 0 0 0 0 9 0
3 9 0 0 0 0 0 0 9
Table 3: Exact design for n = 48 trials constructed from the optimal non-product design
given in Table 2.
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Figure 1: The dependence of w∗1 for the A-optimal product design w∗ ⊗ α∗ on the number of
covariates v2 in Example 1, where Q = (−1, I)T , K = I, v1 = 3, λ1 = 9 and λ2 = λ3 = 1.
Table 2. Whereas the support of the optimal product design is of size 24, the support of
the optimal non-product design is only of size 10. One can also observe that the marginal
treatment design of ξ∗s is w∗, but α∗ is not its marginal covariate design.
Let us demonstrate the usefulness of the sparsely supported designs for constructing the
exact designs by the efficient rounding procedure by Pukelsheim and Rieder [1992]. For
n = 48 trials the rounded product design ξep satisfies ξep(i, z) = 2 for each i and for each
z ∈ {−1, 1}3; the rounded non-product design ξes is given in Table 3. To compare the quality
of the obtained designs, we calculate their efficiencies: eff(ξe) = Φ(NA(ξe/n))/Φ(NA(ξ∗)),
where ξe is an exact design for n trials and ξ∗ is the Φ-optimal approximate design. We have
eff(ξep) = 0.9641 for the rounded product design and eff(ξes) = 0.9991 in the non-product
case. The very high efficiency of the exact design ξes relative to the optimal approximate
design means that ξes is either an optimal exact design, or very nearly optimal.
The efficient rounding method requires that the number of trials n be equal or greater than
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Figure 2: A-efficiencies of the rounded product and non-product designs in Example 1 for
varying number of observations n. Zero efficiency means that for the corresponding n, the
efficient rounding cannot be applied for the design.
the support size of the approximate design. Therefore, the efficient rounding of ξ∗ cannot be
performed for n ≤ 23, as the support size of ξ∗ is 24. However, the rounding of the non-
product ξ∗s can be done even for 10 ≤ n ≤ 23. This is demonstrated in Figure 2, which
shows efficiencies of the respective rounded designs for varying n. Note that the rounded
non-product design is not always more efficient than the rounded product design.
Example 2. Suppose that the responses are affected, besides the treatment effects, by two
qualitative covariates:
y(i, j, k) = τi + µ+ ηj + ρk + ε,
where j ∈ {1, . . . , r} is the level of the first covariate, k ∈ {1, . . . , c} is the level of the second
covariate, and ηj and ρk are the respective covariate effects. In the optimal design literature,
such a model is usually known as two-way elimination of heterogeneity (e.g., see Hedayat
et al. [1988]) or a row-column model (e.g., see Jacroux [1982]), where the trials are split into
r rows and c columns. If the effects of one of the covariates is disregarded, we obtain the
well-known model with block effects. Suppose that all the treatments are of the same interest,
which can be expressed by estimating the treatment effects corrected for the mean τi− τ¯ ; i.e.,
Q1 = Iv1 − 1v11Tv1/v1. Similarly, let K = diag(Ir − 1r1Tr /r, Ic − 1c1Tc /c). Let v1 = 3, r = 3,
c = 5 and λ = (4, 1, 1)T . We shall provide E-optimal designs for estimating AT θ.
The E-optimal marginal covariate design for KTβ is uniform: α∗(j, k) = 1/15 for all
j, k. The optimal criterion value ΦE(NQ2(α∗)) is 0.2, and then the corresponding optimal w∗
calculated using Theorem 2 is given by the vector of treatment weights (0.273, 0.364, 0.364)T .
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ξ(1, j, k) 1 2 3 4 5
1 0.0303 0.0121 0.0303 0.0121 0.0061
2 0.0061 0.0303 0.0121 0.0242 0.0182
3 0.0182 0.0121 0.0121 0.0182 0.0303
ξ(2, j, k) 1 2 3 4 5
1 0 0 0 0.0485 0.0727
2 0.0242 0 0.0727 0.0242 0
3 0.0485 0.0727 0 0 0
ξ(3, j, k) 1 2 3 4 5
1 0 0.0727 0 0.0242 0.0242
2 0.0727 0 0 0 0.0485
3 0 0 0.0727 0.0485 0
Table 4: Optimal non-product design for Example 2. The table contains the values ξ(i, j, k),
where i is the treatment, j is the first covariate level (expressed in rows) and k is the second
covariate level (expressed in columns). For example, the value 0.0121 in row 2 and column 3
of the first “block” of the table means that ξ(1, 2, 3) = 0.0121.
Then, the E-optimal product design w∗⊗α∗ is supported on all the v1×rc = 45 design points,
with values ξ(1, j, k) = 0.0182 and ξ(2, j, k) = ξ(3, j, k) = 0.0242 for each j and k. By solving
the linear program (18), an E-optimal design ξ∗s with a smaller number of support points can
be obtained. Such a design is given in Table 4. The non-product design ξ∗s has a smaller
support of only size 28, as expressed by the large number of zeroes in Table 4. Table 5 gives
the rounded non-product design ξ∗s for n = 40 trials; for this number of trials, the efficient
rounding of the optimal product design cannot be performed because of its large support size
of 48 > n. The efficiency of the exact design obtained by the rounding of ξ∗s is 0.8493.
Example 3. Let us demonstrate the obtained theoretical results in settings, where there is no
interest in the covariates. Consider a model with exponential trend effect, which is considered
to be a nuisance:
y(i, k) = τi + µ+ g(k)β + ε,
where g(k) = ek/
∑
j e
j , k = 1, . . . , d. In each time k = 1, . . . , d, the same number of trials
must be performed, which results in the design constraint
∑
i ξ(i, k) = 1/d for each k. Suppose
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ξ(1, j, k) 1 2 3 4 5
1 1 1 1 1 1
2 1 1 1 1 1
3 1 1 1 1 1
ξ(2, j, k) 1 2 3 4 5
1 0 0 0 2 2
2 1 0 2 1 0
3 2 2 0 0 0
ξ(3, j, k) 1 2 3 4 5
1 0 2 0 1 1
2 3 0 0 0 2
3 0 0 2 2 0
Table 5: Exact design for n = 40 trials constructed from the optimal non-product design
given in Table 4.
that the interest lies in the treatment-control comparisons only; i.e., QT = (−1v1−1, Iv1−1)
and AT = (QT ,0). Let v1 = 4, d = 6, λ = (1, 1, 2, 3)T and consider the A-optimality
criterion.
The A-optimal marginal treatment design w∗ can be found by maximizing ΦA(NQ(w)),
and its values are given by the vector (0.431, 0.249, 0.176, 0.144)T . The A-optimal product
design is then ξ∗ = w∗ ⊗ α, where the marginal covariate design αk = 1/d for k = 1, . . . , d
is implied by the design constraints
∑
i ξ(i, k) = 1/d. An optimal non-product design can
be obtained as in Theorem 3 by solving the linear program with constraints ξ(i, k) ≥ 0 for
all i, k,
∑
i ξ(i, k) = 1/d for all k, and M(ξ)GA = A, where G = diag(M
−1
1 (w
∗),0). The
resulting design ξ∗s , which is supported on 12 design points, is given in Table 6; the optimal
product design is supported on all the 24 points.
Because of the requirement that exactly one trial should be performed in each time mo-
ment, the usual rounding methods cannot be used to obtain efficient exact designs. A natural
rounding method for the sparsely supported non-product designs is to select in each time the
treatment with the highest design value; such a rounded design based on ξ∗s has efficiency
0.8871 and is given in Table 7. Note that it is unclear how the optimal product designs can
be rounded in the current example – these designs do not provide any information on the sug-
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i\k 1 2 3 4 5 6
1 0.0880 0.1667 0.0552 0.0166 0 0.1048
2 0.0787 0 0 0 0.1667 0.0036
3 0 0 0 0.1501 0 0.0260
4 0 0 0.1115 0 0 0.0323
Table 6: Optimal non-product design for Example 3. i – treatment, k – time moment.
i\k 1 2 3 4 5 6
1 1 1 0 0 0 1
2 0 0 0 0 1 0
3 0 0 0 1 0 0
4 0 0 1 0 0 0
Table 7: Exact design constructed from the optimal non-product design given in Table 6.
gested time sequence of the treatments, only the optimal treatment proportions are obtained.
For instance, the aforementioned method would result for ξ∗ in a singular design that selects
the first treatment in each time moment.
5 Discussion
Although D-optimality is very beneficial analytically and computationally in the considered
model, we showed that other eigenvalue-based optimality criteria like A- and E-optimality
are not much more difficult to work with (Theorems 1 and 2). Because the latter place actual
emphasis on the selected system of interest, they seem to be more appropriate in the current
settings.
The use of optimal product designs is also computationally very beneficial, because they
allow one to reduce the v1d-dimensional optimal design problem in the multi-factor model (1)
to two simpler problems of sizes v1 and d for the two marginal models. However, the product
designs suffer from large support sizes, as noted earlier. The support sizes of the product
designs can in some settings be reduced by combinatorial approaches; e.g., by replacing full
factorials by orthogonal arrays as in Graßhoff et al. [2004]. Such reductions of support sizes are
however very dependent on the particular well-studied models with a very regular structure
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that can be made use of in the combinatorial arguments.
To reduce the support sizes in more general settings, we provide an entire class of optimal
designs (see Theorem 3) characterized by linear constraints. Such a characterization allows one
to use linear programming for constructing optimal non-product designs. That the obtained
constraints for optimal designs are linear is particularly useful, because the linear programming
routines tend to provide vertex solutions, which have high numbers of zeros. As a result, the
solvers “automatically” provide designs with small supports. As we demonstrated on examples
in Section 4, it seems that the method tends to allow for significant reductions of the support
sizes. The use of linear programming also means that the algorithm is reliable and fast. Unlike
the combinatorial approaches, the proposed method is not tailored for specific settings – it
can be used for any model of the form (1).
We would like to emphasize that the proposed support reduction method is not particu-
larly tied to the current model (1). As noted earlier, the method was applied for a similar
model by Rosa and Harman [2016]. Moreover, the proposed approach can be used for any
linear regression model where an optimal design ξ∗ with a large support is found, either ana-
lytically or by design algorithms. Then one can find designs that satisfy eitherM(ξ) = M(ξ∗)
orM(ξ)GA = A with a suitably chosen G as in Theorem 3 via linear programming to obtain
vertex solutions. As shown in the present paper, the vertex solutions correspond to designs
that tend to have smaller supports and are therefore generally more useful for practical pur-
poses.
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